200
评论
查看更多
密码过期或已经不安全，请修改密码
修改密码
壹生身份认证协议书
同意
拒绝
同意
拒绝
同意
不同意并跳过
参考资料：
1.Zeng H, Zheng R, Zhang S, et al. Esophageal cancer statistics in C hina, 2011: Estimates based on 177 cancer registries[J]. Thoracic Cancer, 2016, 7(2): 232-237.
2.Liang H, Fan J H, Qiao Y L. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China[J]. Cancer Biology & Medicine, 2017, 14(1): 33.
3.Chen W, Zheng R, Zeng H, et al. The incidence and mortality of major cancers in China, 2012[J]. Chinese journal of cancer, 2016, 35(1): 73.
4.Allum W H, Bonavina L, Cassivi S D, et al. Surgical treatments for esophageal cancers[J]. Annals of the New York Academy of Sciences, 2014, 1325: 242.
5.Van Rossum P S N, Mohammad N H, Vleggaar F P, et al. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends[J]. Nature Reviews Gastroenterology & Hepatology, 2018, 15(4): 235.
6.Chen J, Luo S, Qin S, et al. 760P Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: Analysis of the Chinese subgroup in KEYNOTE-181[J]. Annals of Oncology, 2019, 30(Supplement_5): mdz247. 086.
来源： 万物科学说明书
查看更多
中国医学论坛报
壹生
今日肿瘤
今日循环
今日糖尿病
今日口腔
全科周刊
脱贫地区农副产品网络销售平台
京公网安备 11010202008182号
| 互联网新闻信息服务许可证编号：10120190017